TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03003325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOP2014
Description: AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomies
Description: According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT\< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomies
Description: According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT\< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
Study: NCT02300961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program
Study: NCT04163016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of certolizumab pegol
Description: The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician.
Study: NCT05786651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Within-Subjects Attentional Information
Description: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
Study: NCT00519441

Intervention type: OTHER
Group type: OTHER
Intervention: pH study
Description: All patients will have 48 hour pH study
Study: NCT06592118

Intervention type: OTHER
Intervention: Different Pathological Types (FTC vs PTC)
Description: Comprehensive Comparison of Pediatric and Adolescent Follicular Thyroid Carcinoma and Papillary Thyroid Carcinoma Patients

Intervention type: OTHER
Intervention: Different Pathological Types (FTC vs PTC)
Description: Comprehensive Comparison of Pediatric and Adolescent Follicular Thyroid Carcinoma and Papillary Thyroid Carcinoma Patients
Study: NCT06596265

Intervention type: BEHAVIORAL
Intervention: Fit2Lead Group 1-2
Description: Each park serves anywhere from 2 to 9 feeder schools within these neighborhoods (a target population of 34 000 youth residents aged 12-17 years), and transportation from schools to parks is provided at no cost within a 3-mile radius of a program park. Fit2Lead participants can also enroll in the MDPROS youth summer camp at no charge.~Work assignments support MDPROS operations and recreation staff. Interns in Phase II rotate every 8 weeks for exposure to different job opportunities, supervisors, and mentors.~Duke is conducting a secondary data analysis on data collected as part of the Fit2Lead study.
Study: NCT01683929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucose
Description: The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire.
Study: NCT00515372

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Weekly phone calls lasting about 30 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Lists of professional resources and referral recommendations will be provided.
Study: NCT03837041

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reconditioning Proprioception
Description: Proprioceptive training using Delos Postural Proprioceptive System
Study: NCT03430297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001 240mg Q2W
Description: recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) will be provided by the sponsor. Strength: 240mg/6ml/vial. 240mg, once every two weeks.~Control drug: dacarbazine (1000mg/m2, d1, intravenously, once every three weeks). The dose will be given intravenously over 180 minutes (the infusion time can be prolonged according to the institutional criteria), starting from Week 1, once every 3 weeks, until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine 1000mg/m2 Q3W
Description: The dose of DTIC will be calculated according to the following formula, where the 'X' represents the total mg dose of DTIC: X (mg) = \[body surface area (BSA) x (1000mg/m2)\].~The body surface area (BSA) is defined by Dubois formula: BSA (m2) = 0.007184\* (cm0.725) \* (kg0.425)
Study: NCT03012503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioFreeze
Description: The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
Study: NCT01683929

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sweetner
Description: The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire.
Study: NCT01849627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-ED
Description: This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Balance
Description: Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
Study: NCT04498091

Intervention type: BIOLOGICAL
Intervention: Biological data
Description: Biological data
Study: NCT03742557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV
Description: Ketamine 0.5 mg/kg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV
Description: Ketamine 0.5 mg/kg IV
Study: NCT01615939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.625% with epinephrine 1:300,000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
Study: NCT00821548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrostimulation
Description: Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
Study: NCT02947321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular Nerve RFA
Description: Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. RFA probes will be placed and connected to the RFA generator and the generator is activated. The RFA is performed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Genicular Nerve RFA
Description: Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
Study: NCT04498091

Intervention type: BIOLOGICAL
Intervention: Biological data
Description: Biological data

Intervention type: BIOLOGICAL
Intervention: Biological data
Description: Biological data

Intervention type: BIOLOGICAL
Intervention: Biological data
Description: Biological data

Intervention type: OTHER
Intervention: Clinical data
Description: Clinical data

Intervention type: OTHER
Intervention: Clinical data
Description: Clinical data

Intervention type: OTHER
Intervention: Clinical data
Description: Clinical data

Intervention type: OTHER
Intervention: Clinical data
Description: Clinical data
Study: NCT01820013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customised Dynamic Elastomeric fabric Orthoses
Description: Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
Study: NCT00570830

Intervention type: DEVICE
Group type: OTHER
Intervention: Retisert (fluocinolone acetonide implant)
Description: Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
Study: NCT02397577

Intervention type: OTHER
Group type: OTHER
Intervention: Solid test meal, liquid test meal on two separate occations
Description: 13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
Study: NCT01820013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Serola Sacroiliac Belt
Description: Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
Study: NCT05182281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration and Infrared Therapy
Description: Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm. Whole body vibration and infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared Therapy
Description: Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm.Infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.

Intervention type: OTHER
Group type: OTHER
Intervention: Classical Treatment
Description: 1000 mg Ca and 880 IU vitamin D treatment were given
Study: NCT02435953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
Study: NCT02085967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam 2 mg with bupropion 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006
Study: NCT02941081

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHAT
Description: 1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate
Description: 1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
Study: NCT02781844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mcg rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mcg rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mcg rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mcg rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
Study: NCT02941081

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
Study: NCT00812708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morcher iris diaphragm implantation
Description: Surgical implantation of Morcher iris device(s)
Study: NCT01632696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-124 PGN650 for PET/CT
Description: I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
Study: NCT04524780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracardiac echocardiography
Description: 30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracardiac echocardiography
Description: 30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
Study: NCT04461275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS 2.0
Description: ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis)
Study: NCT02781844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mcg rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mcg rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
Study: NCT01082016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Enhancement Program (SEP)
Description: Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
Study: NCT01980563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Study: NCT00321373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate Influenza Vaccine GSK1247446A - 2 different formulations
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate Influenza Vaccine GSK1247446A - 2 different formulations
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: Single dose, Intramuscular injection
Study: NCT00918580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumoccocal Conjugate Vaccine
Description: 2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
Study: NCT01076426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-biotics
Description: Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
Study: NCT01980563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined monitoring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined monitoring
Study: NCT01105481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride add-on
Description: At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo add-on
Description: For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
Study: NCT03390946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poor responder group adjuvant chemotherapy
Description: Poor responder group (necrosis ≤ 90%)~: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~B. Resection of tumor~C. Adjuvant chemotherapy~1. Poor responder group (necrosis ≤ 90%)~   * week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~2. Good responder group (necrosis \> 90%)~   * week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Good responder group adjuvant chemotherapy
Description: Good responder group (necrosis \> 90%)~: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin
Study: NCT03021785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK001
Description: TK001 will be administered intravitreal injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK001
Description: TK001 will be administered intravitreal injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK001
Description: TK001 will be administered intravitreal injection.
Study: NCT01076426

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oligosaccharide
Description: oligosaccharide one pack per day
Study: NCT03897764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative superior hypogastric plexus block
Description: SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.
Study: NCT04240535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 50 UNT [Botox Cosmetic]
Description: Injections to the Depressor Anguli Oris

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OnabotulinumtoxinA 50 UNT [Botox Cosmetic]
Description: Injections to the Depressor Anguli Oris
Study: NCT03897764

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intraoperative superior hypogastric plexus block
Description: SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.